Patents by Inventor Beat Kunz

Beat Kunz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for determining inhibitors of neurotrypsin
    Patent number: 7897364
    Abstract: The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, characterized in that the compound is incubated together with neurotrypsin, a variant thereof or a fragment comprising the protease domain and with a protein or peptide comprising agrin, a variant thereof or a fragment comprising the ?- or the ?-cleavage site of agrin, in an aqueous buffer solution, and the amount of cleavage of agrin is measured. Additionally, the invention relates to inhibitors of neurotrypsin found by this method, in particular to compounds of formula wherein Hal1 and Hal2 are fluorine, chlorine or bromine, and the use of such inhibitors for the treatment and/or prophylaxis of diseases caused by deficiency of synapses, for example skeletal muscle atrophy, schizophrenia, and cognitive disturbance.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: March 1, 2011
    Assignee: University of Zurich
    Inventors: Peter Sonderegger, Stefan Hettwer, Marc F. Bolliger, Birgit Dreier, Beat Kunz, Daniel Lüscher, Raymond Reif, Susanne Sales
  • METHOD FOR THE DETECTION OF THE IN-VIVO ACTIVITY OF NEUROTRYPSIN, USE OF THE METHOD AND USE OF THE C-TERMINAL, 22-KDA FRAGMENT OF AGRIN AS BIOMARKER IN DIAGNOSIS AND MONITORING OF NEUROTRYPSIN-RELATED DISTURBANCES
    Publication number: 20100240083
    Abstract: Method for the detection of the in-vivo activity of neurotrypsin wherein the amount of the 22-kDa-fragment of agrin is measured in a sample taken from a patient and the measured amount of the 22-kDa-fragment of agrin in the sample is used to calculate the activity of neurotrypsin, use of the method for diagnosis and monitoring of neurotrypsin-related disturbances and use of the 22-kDa-fragment of agrin as biomarker for neurotrypsin-related disturbances.
    Type: Application
    Filed: April 26, 2008
    Publication date: September 23, 2010
    Applicants: NEUROTUNE AG, UNIVERSITAT ZURICH
    Inventors: Peter Sonderegger, Stefan Hettwer, Alexander Stephan, Kazumasa Miyai, Beat Kunz
  • Inhibitors Of Neurotrypsin
    Publication number: 20090170950
    Abstract: The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, characterized in that the compound is incubated together with neurotrypsin, a variant thereof or a fragment comprising the protease domain and with a protein or peptide comprising agrin, a variant thereof or a fragment comprising the ?- or the ?-cleavage site of agrin, in an aqueous buffer solution, and the amount of cleavage of agrin is measured. Additionally, the invention relates to inhibitors of neurotrypsin found by this method, in particular to compounds of formula wherein Hal1 and Hal2 are fluorine, chlorine or bromine, and the use of such inhibitors for the treatment and/or prophylaxis of diseases caused by deficiency of synapses, for example skeletal muscle atrophy, schizophrenia, and cognitive disturbance.
    Type: Application
    Filed: March 29, 2006
    Publication date: July 2, 2009
    Inventors: Peter Sonderegger, Stefan Hettwer, Marc F. Bolliger, Birgit Dreier, Beat Kunz, Daniel Luscher, Raymond Reif, Susanne Sales